Recommendations for Reporting Treatment of Aortic Graft Infections  by Teebken, O.E. et al.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 43 (2012) 174e181Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comRecommendations for Reporting Treatment of Aortic Graft Infections
O.E. Teebken a,*, T. Bisdas a, O. Assadian b, J.-B. Ricco c
aDivision of Vascular Surgery, Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, OE 6210, 30625 Hannover,
Germany
b Institute of Hospital Hygiene, Medical University of Vienna, Vienna, Austria
cDepartment of Vascular Surgery, University Hospital Jean Bernard, Poitiers, France
WHAT THIS PAPER ADDS
 The purpose of these recommendations is to provide a standard format for reporting standardised epidemiologic data and treat-
ment of vascular aortic graft infection (VGI) to improve the comparison of clinical outcomes between different therapeutic
approaches and different study populations. These recommendations are, to our knowledge, the ﬁrst addressing a standardised,
structured approach raised from the existent heterogeneity between different study protocols and reported results published in
clinical trials.a r t i c l e i n f o
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The purpose of these recommendations is to provide a standard format for reporting treatment results
and standardised epidemiologic data after aortic vascular graft infection to improve the comparison of
clinical outcomes between different therapeutic approaches and different study populations. Analytical
reporting standards for patients’ characteristics, type and extent of the disease, type of treatment and
study design are described. Adherence to these recommendations will improve clinical relevance, quality
and comparability of future studies dealing with aortic vascular graft infections.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The purpose of these recommendations is to provide a standard
format for reporting standardised epidemiologic data and treat-
ment of aortic graft infection (VGI) to improve the comparison of
clinical outcomes between different therapeutic approaches and
different study populations. These recommendations are, to our
knowledge, the ﬁrst addressing a standardised, structured
approach (Fig. 1) raised from the existent heterogeneity between
different study protocols and reported results published in clinical
trials. Speciﬁcally, the low incidence of aortic VGIs (<4%) requires
the inclusion of a large number of patients to support any rando-
mised controlled trial comparing different types of treatment ortions on this paper, please go
x: þ49 511 532 5404.
over.de, teebken@web.de
ciety for Vascular Surgery. Publisheinvestigating epidemiologic risk factors.1,2 Neither national health
care nor commercial industries is likely to get involved in such cost-
intensive multicentre studies.2 At present, only case reports,
retrospective studies, meta-analyses, propensity-score based
analyses and multicentre registries can provide information about
the different treatment strategies. Thus, it is of importance that
reported results from different authors are comparable. Adherence
to these standards will improve clinical relevance and quality of
future studies dealing with aortic VGIs. These recommendations
are by no means guidelines for diagnosis and treatment of aortic
VGI, but a resource to better report clinical studies.
A. Reporting ‘Patients’ Characteristics’
Details of study cohort
An analytical description of study cohorts is recommended to
avoid duplicated studies and reporting on various outcomes withd by Elsevier Ltd. All rights reserved.
Figure 1. Schematic presentation and synopsis of the reporting standards for treatment results for vascular graft infections (VGI) in the abdominal aorta.
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reviews, meta-analyses, non-randomised controlled trials and
registries. Therefore, relevant baseline information must be given
for each patient.Recommendations
 Deﬁnition of patient cohort including age, sex, previous
vascular surgery or interventions, and time interval between
initial operation and onset of symptoms is recommended.
Aﬂowchart of the total cohort fromwhich a particular population
is being selected is also recommended including the total number of
patients fromwhom this selected patient population is drawn.Co-morbidities and risk factors
Analysis of the outcomes and comparison between studies
necessitate an exact deﬁnition of patients’ characteristics and
risk stratiﬁcation based on co-morbid medical conditions. In
addition to demographic details, clinical manifestations of aortic
VGI vary epidemiologically depending on the onset of infection.
Presentation of VGI may be distinguished as early- or late-onset
infection based on the normal disappearance of periprosthetic
collections up to 4 months after surgery.3 In early-onset infec-
tions (‘<4 months’ after graft implantation) the patient may be
systemically septic with fever and leucocytosis. Systemic infec-
tion, local wound infection, abdominal discomfort and graft
occlusion may be present. Late-onset infections (‘>4 months’
after graft implantation) often present with non-speciﬁc clinical
signs and symptoms.4 However fever is present in the majority
of cases with some of them having various complications of
aortic VGI, such as gastrointestinal bleeding due to erosion of
the graft into the gastrointestinal tract, false aneurysm or
hydronephrosis.4Recommendations
 It is recommended to report the classiﬁcation of aortic graft
infection as ‘early’ (<4 months) or ‘late’ (4 months) with
respect to the time of clinical infection after graft
implantation.5
 The following co-morbidities should be reported: arterial
hypertension, obesity (body mass index), diabetes mellitus
(type I, type II, conservative treatment, drug therapy and
insulin dependence), chronic obstructive pulmonary disease
(forced expiratory volume, FEV1), coronary artery disease,
hypercholesterolaemia, myocardial infarction (<6 months),
peripheral vascular disease (Fontaine or Rutherford classiﬁca-
tion) and renal disease (glomerular ﬁltration rate (GFR) at the
time of presentation, dialysis or not), and smoking status.
 The use of American Society of Anaesthesiologists (ASA) score
is recommended.
Back et al. provideda satisfactoryandcomprehensiveoverview for
the most common risk factors predisposing to bacterial contamina-
tion and prosthetic graft infection classifying them in patient-related
(malignancy, lymphoproliferative disease, autoimmune disease,
immunosuppression, corticosteroid administration, liver disease/
cirrhosis, chemotherapy, malnutrition, diabetes mellitus and chronic
renal insufﬁciency/end-stage renal disease) and perioperative (pro-
longed preoperative hospitalisation, infection in a remote site, ‘break’
in aseptic technique, emergency/urgent operation, re-operative
vascular procedure, extended operating time and postoperative
wound complication).4 Additional risk factors can be considered such
as any nose/throat or urinary tract colonisation (colonisation risk of
methicillin-resistant Staphylococcus aureus (MRSA)), other invasive
procedures at the meantime between initial operation and diagnosis
of infection (peripheral or cardiac angiography and endovascular
aortic repair) and all cavity-related operations (e.g., cholecystectomy
after abdominal aortic repair, coloscopy with biopsy and dental
extraction without systemic antibiotic coverage).6
Table 1a
Criteria of Centers for Disease Control and Prevention (CDC) for superﬁcial surgical
site infection (SSI).5
Superﬁcial incisional surgical site infection
(must meet the following criterion):
Infection occurs within 30 days after the operative procedure
and
involves only skin and subcutaneous tissue of the incision
and
patient has at least 1 of the following:
a) purulent drainage from the superﬁcial incision
b) organisms isolated from an aseptically obtained culture of ﬂuid or tissue
from the superﬁcial incision
c) at least one of the following signs or symptoms of infection: pain
or tenderness, localised swelling, redness, or heat, and superﬁcial
incision is deliberately opened by surgeon and is culture-positive
or not cultured. A culture-negative ﬁnding does not meet this criterion.
d) diagnosis of superﬁcial incisional surgical site infection by a surgeon
or attending physician
There are 2 speciﬁc types of superﬁcial incisional surgical site infections:
 Superﬁcial incisional primary (SIP): a superﬁcial incisional SSI that
is identiﬁed in the primary incision in a patient who has had an
operation with 1 or more incisions
 Superﬁcial incisional secondary (SIS): a superﬁcial incisional SSI that
is identiﬁed in the secondary incision in a patient who has had an
operation with more than 1 incision [e.g. donor site (leg) incision
to harvest autologous veins for insitu reconstruction of an abdominal
vascular graft infection].
Reporting instructions:
 Do not report a skin suture abscess with minimal inﬂammation
and discharge conﬁned to the points of suture penetration,
as an infection.
 Do not report a localised stab wound infection as SSI, instead
report as skin or soft tissue infection depending on its depth.
 If the incisional site infection involves or extends into the fascial
and muscle layers, report as a deep incisional SSI.
Table 1b
Criteria of Centers for Disease Control and Prevention (CDC) for deep surgical site
infection (SSI).5
Deep incisional surgical site infection
(must meet the following criterion):
Infection occurs within 30 days after the operative procedure if no implant
is left in place or within 1 year if implant is in place and the infection
appears to be related to the operative procedure
and
involves deep soft tissues (e.g. fascia and muscle layers) of the incision
and
patient has at least 1 of the following:
a) Purulent drainage from the deep incision but not from
the organ/space component of the surgical site
b) A deep incision spontaneously dehisces or is deliberately opened
by a surgeon and is culture-positive or not cultured when the patient
has at least 1 of the following signs or symptoms: fever (>38 C),
or localised pain or tenderness. A culture-negative ﬁnding does not
meet this criterion.
c) An abscess or other evidence of infection involving the deep incision
is found on direct examination, during reoperation, or by
histopathologic or radiologic examination.
d) Diagnosis of a deep incisional SSI by a surgeon or attending physician
There are 2 speciﬁc types of deep incisional SSI:
 Deep incisional primary (DIP): a deep incisional SSI that is identiﬁed
in a primary incision in a patient who has had an operation with one
or more incisions.
 Deep incisional secondary (DIS): a deep incisional SSI that is identiﬁed
in the secondary incision in a patient who has had an operation with
more than 1 incision [e.g. donor site (leg) incision to harvest autologous
veins for in-situ reconstruction of an abdominal vascular graft infection].
Reporting instructions:
Classify infection that involves both superﬁcial and deep incision sites
as deep incisional SSI.
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 All risk factors should be documented. In cases of invasive
procedures or abdominal operations, the exact character of the
procedure as well as the time period between the initial aortic
repair and the secondary procedure should be reported.
Clinical presentation of patients
The clinical presentation of patients suffering from aortic VGIs
varies between the absence of any symptomatologyandup to severe
sepsis or anastomotic rupture with hypovolemic shock.1,2,4,7e9 For
example, an unexplained leucocytosis with concomitant increase of
C-reactive protein (CRP) and fever may be the only clinical or labo-
ratory signs of aortic VGI.2 In other cases, peripheral septic embo-
lisation, septic shock, ileus, haematemesis, haematuria or
abdominal distension are the clinical manifestations.1,2,4,7e9 Thus,
a well-documented clinical and laboratory status of the patients at
the time of aortic VGI diagnosis is required in order to provide
a sufﬁcient and analytical overview of the study cohort.
Recommendations
 Aortic VGI should be classiﬁed according to the clinical
presentation as ‘symptomatic’ or ‘asymptomatic’. In case of
symptomatic patients, the treatment should be classiﬁed as
‘elective, urgent (within 24 h) or emergent (as soon as
possible)’.
 All symptoms of patients should be recorded at the time of
presentation. In addition, body temperature, leucocytes and C-
reactive protein levels and, if possible, procalcitonin, a more
speciﬁc marker for bacterial infection,10 should be added.
 In patients with graft-enteric or graft-ureteral ﬁstula, haemo-
globin levels and haematocrit are mandatory. Finally, haemo-
dynamic condition prior to surgery (stable, with or without
preceding resuscitation, shock, intubated and unstable) should
be documented.
 Local complications should be documented as well.4 In this
context, application of the criteria of Centers for Disease
Control and Prevention for superﬁcial and deep surgical site
infection (Tables 1a and 1b) may facilitate the description of
local complications.5
Radiological ﬁndings
Vascular imaging is essential for the diagnosis, treatment and
postoperative management of aortic VGI.3,11 Contrast-enhanced
computed tomography (CT) remains the most speciﬁc and
feasible examination.3,4,11 Ultrasonography is a readily available
imaging technique that can be performed urgently at the bedside of
critically ill patients or in emergency.4 Upper gastrointestinal
endoscopy or ureteroscopy remains an important diagnostic
modality for graft-enteric and graft-ureteral ﬁstula.2,4 Fluorodeox-
yglucose-(18F)-positron emission tomography-CT (18FDG-PET-CT)
has been proposed as an additional investigation for the diagnosis
of aortic VGI, although its speciﬁcity and sensitivity have been
challenged.3,4,11,12 The accuracy of indium-111-labelled white blood
cell-scan approaches 80e90% to detect an aortic VGI.4 Drawback
remains that all radionuclide imaging techniques do not provide
anatomic details and that in early postoperative course (3e6
months) the uptake is non-speciﬁc in the framework of healing and
perigraft inﬂammatory reaction.4,13 Finally, CT-guided aspiration of
cavitary perigraft ﬂuid collections is being used to differentiate
uninfected seroma from abscess formation.2,4
Table 2
Radiological ﬁndings suggestive of vascular graft infection in contrast-
enhanced computed tomography (CT)-scan.11
CT-scan ﬁnding
Presence of ectopic gas
Pseudoaneurysm formation
Presence of perigraft ﬂuid (<20 Hounsﬁed Units)
Discontinuity of the aneurysmal sac
Increased amount of soft tissue (>5 mm) between the graft and the
surrounding aneurysmal sac
Hydronephrosis
Adjacent vertebral or bony osteomyelitis
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 CT-scan ﬁndings as well as additional investigations should be
reported for the pre- as well as the postoperative phases. The CT-
scan ﬁndings that deserve mention are loss of normal tissue
planes of the retroperitoneal or perigraft structures, perigraftﬂuid
density and volume of oral contrast media used concomitantly to
intravenous contrast to analyse adjacent enteric structures.
 The indication for 18FDG-PET-CT investigation as well as the
respective ﬁndings as deﬁned by standard uptake value (SUV)
should be reported.12 If the institution’s policy comprehends
18FDG-PET-CT as regular follow-up investigation for the
surveillance of these patients, reporting of SUVmax-distribution
during follow-up is recommended.
 In case of CT-guided aspiration, the indication and details
concerning the microbiological ﬁndings should be reported.
Microbiological specimens
Microbiological investigations may support diagnosis of aortic
VGI if specimens are obtained in such a manner that microorgan-
isms potentially causative for aortic VGIs are yielded, and not
colonisation ﬂora with no relevance for a suspected aortic VGI.
Optimal results will be achieved with specimens obtained directly
from the infection site. Such direct material may include explanted
grafts, extra- or intra-operatively obtained tissue biopsies from the
infected area and material aspirated from perigraft ﬂuid collection,
and also indirect material such as blood cultures may yield
important information. Blood cultures may be often negative,
particularly in late-onset and less frequently in early-onset
infection.14
Obtained specimens may be investigated using a number of
techniques such as direct streaking swabs on agar plates, broth
culture, homogenisation of tissue specimens with serial dilution
techniques, sonication of the graft to enhance the recovery of
bioﬁlm-forming organisms from graft or infected material.15
The report of microbiological specimens is decisive for a valu-
able evaluation of therapy and clinical results.2,8 The demon-
stration of specimens from pre-, intra- and postoperative phase is
considered ideal, if feasible and possible.16 Relevant ‘preoperative
samples’ are blood cultures through central and peripheral
venous catheters or direct vein puncture, wound specimens,
drainage ﬂuid (in cases of an early-onset postoperative aortic VGI)
and nose/throat swabs in case of MRSA colonisation and urinary
samples. In any case, all responsible microorganisms should be
classiﬁed according to their type (Gram-positive or -negative,
fungi, etc.) and speciﬁc therapy concepts for high-virulent
microorganisms (e.g., Pseudomonas aeruginosa) should be
mentioned. Moreover, it has to be clear how many individuals
showed evidence of more than one microorganism in the
respective microbiological specimens.
Careful assessment is needed for microorganisms isolated
from overlying wounds or sinuses, as such microorganisms may
represent colonising ﬂora, for example, MRSA, but may be
wrongly interpreted as causative agent.14 Relevant ‘intra-opera-
tive samples’ are standard specimens obtained from the graft
surfaces, the perigraft ﬂuid/pus and the explanted graft. It is
worth noting that a considerable number of specimens may be
negative.2,7,17 This fact does not exclude an infection but should be
known. In cases of homograft implantation, specimens from the
homograft as well as from the storage medium in case of cry-
opreserved arterial homografts should be performed and reported
in order to assess the absence of contamination of the homograft
and to exclude any association to postoperative infection.16
Finally, ‘postoperative samples’ are blood cultures, drainage ﬂuidand wound specimens (e.g., in case of wound-healing delay).
Microbiological specimens of adjacent organs (urinary tract and
gut) stay as equally relevant.Recommendations
 An extensive analysis of all relevant microbiological specimens
and a comparison between pre-, intra- and postoperative
specimens is recommended in order to assess the effectiveness
of treatment.
 A speciﬁc analysis of patients with positive intra-operative
microbiological results is recommended in order to assess the
inﬂuence of this factor on the outcome.
 All microorganisms should be classiﬁed according to their type
and adjuvant measures for the treatment of high-virulent
microorganisms should be mentioned.
 In case of aortic VGI caused by more than one micro-organism,
details regarding the number and type of pathogens are
mandatory. In this case, speciﬁc analysis of those patients
would assess the inﬂuence of this factor on the outcome.B. Deﬁning ‘Type and Extent of Disease’Deﬁnition of aortic VGI
Recommendations pertaining to the deﬁnition of aortic VGI
have not been published previously.2 Additionally, there is no
widely accepted classiﬁcation of aortic VGI.2 The diagnosis of
aortic VGI is usually made on the basis of clinical ﬁndings, sup-
ported by radiological and microbiological investigations. Most
commonly used criteria are the presence of clinical manifesta-
tions of local and systemic infection (e.g., fever, leucocytosis,
erythema and swelling) in combination with intra-operative
signs of infection adjacent to the graft (e.g., pus) with positive
results of microbiological investigations17 and radiological
(contrast-enhanced CT scan and 18FDG-PET-CT) ﬁndings7,9,18,19
(Table 2). Microbiological investigations may include investi-
gating blood cultures or intra-operatively obtained specimens
using swabs or tissue/graft samples. However, in several studies
a signiﬁcant number of patients show negative intra-operative
microbiological specimens. In these cases, well-deﬁned epide-
miologic criteria for VGIs are required.Recommendations
 A precise deﬁnition of the aortic VGI should be provided in
every study. In cases of negative intra-operative microbiolog-
ical samples and/or blood cultures, the exact criteria leading to
the ﬁnal diagnosis of aortic VGI must be described.
Table 3a
Criteria of Centers for Disease Control and Prevention (CDC) for organ/space-organ/
space surgical site infection (SSI).5
Organ/Space-Organ/Space Surgical Site Infection
must meet the following criterion
Infection occurs within 30 days after the operative procedure if no implant is
left in space or within 1 year if implant is in place and the infection appears
to be related to the operative procedure
and
infection involves any part of the body, excluding the skin incision, fascia,
or muscle layers, that is opened or manipulated during the operative
procedure
and
patient has at least one of the following:
a) purulent drainage from a drain that is placed through a stab wound
into the organ/space
b) organisms isolated from an aseptically obtained culture of ﬂuid or tissue
in the organ/space
c) an abscess or other evidence of infection involving the organ/space
that is found on direct examination, during reoperation, or by
histopathologic or radiologic examination
d) diagnosis of an organ/space SSI by a surgeon or attending physician
Table 3b
Criteria of Centers for Disease Control and Prevention (CDC) for arterial infection.5
Arterial infection
must meet at least 1 of the following criteria
a) Patient has organisms cultured from arteries or veins removed during
a surgical operation and blood culture not done or no microorganisms
cultured from blood
b) Patient has evidence of arterial or infection seen during a surgical
operation or histopathologic examination
c) Patient has at least 1 of the following signs or symptoms with no other
recognised cause: fever (>38 C), pain, erythema, or heat at involved
vascular site and more than 15 colonies cultured from intravascular
cannula tip using semi-quantitative culture method and blood culture
not done or no microorganisms cultured from blood
d) Patient has purulent drainage at involved vascular site and blood
culture not done or no organisms cultured from blood
O.E. Teebken et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 174e181178 In this context, appliance of the criteria of Centers for Disease
Control and Prevention (CDC, Atlanta, GA) used for surveillance
purpose in microbiological studies is recommended (Tables 3a
and 3b).5
Classiﬁcation of aortic VGIs (extent of the disease)
The modiﬁed Bunt’s classiﬁcation has been proposed as
a comprehensive classiﬁcation for the description of the extent of
graft involvement.4,20 According to this classiﬁcation, aortic VGI of
the abdominal aorta can be classiﬁed either as P0 graft infection
(infection of cavitary graft, e.g., aorto-bi-iliac graft) or as P2 graft
infection (infection of extra-cavitary portion of a graft whose origin
is cavitary, e.g., aorto-bifemoral graft). Infected aortic stent grafts
can be classiﬁed as P0 graft infection. Graft-organ (-enteric and
-ureter) erosion, graft-organ ﬁstula and aortic stump sepsis after
excision of an infected aortic graft are described in this classiﬁca-
tion as separate entities and not as secondary graft infections.4,20 P1
(infection of a graft whose entire anatomic course is non-cavitary)
and P3 graft infections (infection involving a prosthetic patch
angioplasty) are of no importance for the classiﬁcation of
aortic VGIs.
Recommendation
 The use of the modiﬁed Bunt’s classiﬁcation for the description
of aortic VGI (type and extent) is recommended.C. Reporting ‘Type of Treatment’Open surgical procedure (extra-anatomic or in-situ
reconstruction)
The surgical procedure should be analytically described.
Parameters of special interest are surgical access (e.g., trans-
peritoneal or retroperitoneal approach), infra- or suprarenal
aortic clamping, the presence of pus intra-operatively around the
graft, extensiveness of tissue debridement, intra-abdominal lavage,
the use of ‘antiseptics’ or ‘antibiotics’ with their respective
concentration and amount and additional procedures such as
omentoplasty or insertion of ureteral splint and treatment adjuncts
(e.g., antibiotic-loaded polymethyl-methacrylate beads, vacuum
assisted devices and coverage with muscular ﬂaps in the groin).
Furthermore, administration of perioperative antibiotic prophy-
laxis, class of antibiotic, time of administration before skin incision
and dosage must be mentioned. Type of narcosis, anaesthetics,
complexity of surgery (e.g., single vs. multiple procedures during
the same session and occasional use of cardiopulmonary bypass) as
well as any blood transfusion should be reported. Finally, the type
of anastomoses should be documented in order to facilitate the
comparison between similar patients from different studies.
Duration of surgery deﬁned as skin incision to closure time in
minutes should be provided.Recommendations
 Meticulous description of the surgical procedure including all
the above-described parameters is recommended.
 Peri- and intra-operative antibiotic prophylaxis must be
mentioned.
 Exact description of the anatomical locations of graft anasto-
moses after arterial reconstruction, extra-anatomical or in-situ
is mandatory.
 In case of graft irrigation, without graft removal, a description
of the irrigation agent including concentration, amount,
number, anatomical location of drainages and duration of
irrigation is required.Type of graft(s)
A variety of grafts are available for in-situ- or extra-anatomical
arterial reconstruction following aortic VGI, for example, autolo-
gous vein, arterial human allograft (cryopreserved or fresh), silver-
coated polyester graft and antibiotic-bonded graft.17 It is essential
to describe these grafts in detail (manufacturer), and indicate if the
graft is available for general use or speciﬁc to this study. Further-
more, the authors should discuss the reasons for their choice,
institution policy and selection criteria for a particular modality of
treatment.Recommendations
 The following details regarding the used graft(s) are recom-
mended: manufacturer’s name, type of material (polyethylene-
terephthalate or polytetraﬂuoroethylene (PTFE)), number of
implanted grafts, length and diameter.
 The selection criteria including limitations or drawbacks,
institution policy for the respective graft should be analysed.
 Additional procedures such as impregnation of graft with
antibiotics should be documented.
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Arterial or venous homografts, as biological substitutes, remain
a therapeutic approach used in some countries and some authors
advocate their use with excellent outcomes,2,19,21 but others report
signiﬁcant complications or limitations (aneurysmal degeneration,
rupture, late stenosis, cost and availability).1,9 For a valuable eval-
uation of this therapeutic approach, speciﬁc information is
required.
Recommendations
 Type of homografts (cryopreserved or fresh) and administra-
tion or not of immunosuppressive therapy should be reported.
 Name of tissue bank(s),1 which provided the grafts since
different cryopreservation and decontamination protocols
between the banks may inﬂuence the results, is mandatory.
 The report of speciﬁc details of the cryopreservation protocol
including antibiotic solution for storage and decontamination,
and storage period is recommended.
Endovascular abdominal aortic repair
Several institutions advocate endovascular repair of treatment
of aorto- or prosthetic-enteric ﬁstulas.22 However, its exact role and
effectiveness still need to be addressed,23 albeit encouraging and
comparable outcomes to open repair have been demonstrated.22
Indications for endovascular abdominal aortic repair of
prosthetic-enteric ﬁstulas remain (1) unstable patients suffering
haemorrhagic shock (bridge therapy to a second-stage open
surgery) and (2) patients unﬁt for surgery.
Recommendations
 The exact indications for choosing endovascular repair of
aorto- or prosthetic-enteric ﬁstulas should be reported.
 Details regarding the implantation technique (vascular access,
sheath, wires and stent graft (manufacturer, length and diam-
eter)) and the post-procedure outcomes should be provided in
accordance to the clinical practice guidelines for endovascular
abdominal aortic aneurysm repair.24
Postoperative management and surveillance protocol
At present, there are no guidelines regarding the antimicrobial
postoperative management of patients with aortic VGI.2 While
some authors recommend lifelong antibiotic therapy,25 othersTable 4
Important complications during the perioperative period of the treatment of vascular gr
Events Deﬁnitions and recommendati
Ischaemic complications Peripheral or visceral, reported
limb ischaemia; spinal cord isc
Neurological complications Cerebral bleeding, stroke, tran
Acute Renal failure First time need for haemodialy
Renal insufﬁciency/dysfunction Serum creatinine increase of >
Myocardial dysfunction Deﬁnition is mandatory: eleva
Major blood loss and transfusion Episode of major internal or ex
or necessitates transfusion (pe
Prolonged intubation
Prolonged intermediate-care-unit
(ICU) length of stay
Infection in other organ Specify pneumonia, wound, ur
Endocarditis Imaging modalities should beadvocate a 4e6 weeks of antibiotic treatment.2 Thus, demonstra-
tion of the institution protocol regarding the postoperative
management of patients with aortic VGI is essential. In this context,
the surveillance protocol of the patients including the exact follow-
up investigations (e.g., ultrasound, CT scan, indium-111 white blood
cell-scan, 18FDG-PET-CT-scan, etc.) and microbiological examina-
tions should be described. Patients lost to follow-up must be
counted at all reported time points to prevent selective follow-up of
survivors.
Recommendations
 The surveillance protocol must include details about: (1) type
and duration of antibiotic treatment, (2) time intervals
between the follow-up investigations and (3) imaging
modalities.
 The method used for the follow-up should be described (letter
to the patient, telephone contact, information from the
attending physician or general practitioner and access to the
national death registry or health insurances).
 Patients should be censored at their last known date of clinical
and radiological investigation; otherwise, the criterion for
patients’ censoring should be deﬁned.D. Reporting ‘Study Design’
Study design and end points
The study design and methodology must be explicitly deﬁned.
Main goals of treatment in cases of aortic VGI are: (1) to preserve
the patient’s life, as ﬁrst priority, (2) to avoid limb loss and (3) to
avoid any graft-related complications including reinfection.4
Recommendations
 The use of ‘primary’ and ‘secondary’ end points is encouraged.
We proposed as primary end points death and major limb
amputation, because these are the threatening situations in the
early phase of aortic VGI. Secondary end points should include
‘graft-related’ complications such as reinfection or recurrence
of infection, occlusion, degeneration and rupture plus other
complications deﬁned as ‘non-graft-related’ complications.
Regarding reinfection or recurrence of infection, which can be
used in some series as the ‘primary’ end point, an extensive analysis
of the clinical, microbiological and radiological manifestations,
leading to the diagnosis, is recommended.aft infections in abdominal aorta.
ons
in aggregate, and separately for all types observed, such as intestinal ischaemia,
haemia
sient ischaemic attack, amaurosis fugax, paraplegia, etc.
sis
50% from baseline
ted cardiac enzyme, new Q wave, etc
ternal bleeding that causes death, hospitalisation or permanent injury
rioperative amount of transfused blood should be mentioned)
inary tract infection etc. (always according to CDC-criteria)
described
Table 5
Ideal manuscript structure based on the suggested recommendations for reporting treatment of aortic vascular graft infections.
Exemplary manuscript structure
Introduction
e Point out the gap in current scientiﬁc knowledge and explain how the study ﬁlls this gap.
e Which is the current status regarding the treatment of vascular graft infections?
e Which were the reasons for the conduction of the study?
e Which was the hypothesis or which were the goals of the study?
e What is the question at study?
Patients and Methods
e How was ethical approval for the conduction of this study obtained?
e Study period?
e How many patients were included?
e Which was the study design (randomised, case-control study, retrospective, etc.)?
e Which end points have been analysed (primary: e.g. mortality, secondary: e.g. freedom from reinfection)?
e How were the end points (e.g. reinfection) or other relevant terms of the study (e.g. vascular graft infection, infected aneurysm etc) deﬁned (provide references)?
e Are the exact criteria leading to the ﬁnal diagnosis of VGI described?
e Which graft(s) were implanted (either for in-situ- or extra-anatomic reconstruction) and which are their special characteristics?
e What were the steps of the surgical or interventional procedure?
e Which was the postoperative management (surveillance, sort and duration of antibiotic therapy)?
e Which statistical methods were used for data analysis?
Results
e Which were the patients’ characteristics and co-morbidities?
e How many patients had an early or late vascular graft infection?
e Which were the clinical symptoms of patients at the time of diagnosis, their risk factors, their laboratory results and the observed local complications?
e Which diagnostic modalities were used and which respective ﬁndings (e.g. contrast-enhanced CT-scan, gastrointestinal endoscopy or other) were obtained?
e How many patients underwent additional investigations by doubtful radiological and clinical ﬁndings and which were the respective results?
e Which was the extent of the disease according to Bunt’s classiﬁcation in your patients?
e What kind of microbiological specimens were gained prior to operation from the patients? How many specimens were positive to one or more microorganisms
and which were the responsible pathogens? How many patients had no microbiological specimens prior to operation?
e How many patients underwent elective, urgent, within 24 h or ‘as soon as possible’ surgery?
e Which were the intra-operative ﬁndings (e.g. how many patients showed pus intra-operatively)? How many patients underwent adjuvant measures
(e.g. omentoplasty, ureteral splint etc)? Which antibiotics were administered perioperatively? Which were the mean/median operation time
and the mean/median amount of blood transfusion? How many patients were operated with cardiopulmonary bypass? Which were the performed types
of anastomoses and how many patients received each type? Which were the characteristics of the vascular grafts (route, diameter and length)
used for reconstruction?
e Which were the microbiological results from the intra-operative specimens? How many patients showed positive and negative results respectively?
In positive specimens, which were the pathogens? How many patients showed a contamination with more than one pathogen? Were there any individuals
without any evidence for microorganisms in intra-operative specimens?
e What kind of postoperative microbiological specimens were gained and in how many patients? How many patients showed positive and negative results,
respectively? In positive specimens, which were the pathogens? How many patients showed a contamination with more than one pathogen?
e Which were the results of the analysis of the primary end points (e.g. mortality)?
 30-day and in-hospital mortality?. Which were the reasons for death? Which were the results of the microbiological investigation in these patients?
 Mean follow-up? How many patients were lost during the surveillance and why? Which were the reasons for late death? Which were the survival rates?
e Which were the results of the analysis of the secondary end points? For example for reinfection:
 How many patients showed a reinfection? How was each reinfection diagnosed and conﬁrmed? Which were the responsible pathogens? Which were
the treatment and the outcomes in those patients?
Discussion
e Is the new information provided by the study clearly state?
e Are the implications of the study results and their clinical application discussed?
e Are possible study limitations recognised and discussed?
Conclusions
e Was the question at study answered?
e Is the conclusion based and supported by the generated results?
e Are the conclusions limited to the boundaries of the study?
O.E. Teebken et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 174e181180Early and late mortality
All-cause mortality (in-hospital, 30-day) should be reported,
rather than only vascular or cardiac mortality. Preferably, long-
term follow-up should be provided at 6 months and every year
until 10 years and should be depicted by actuarial estimates
with 95% conﬁdence intervals. Mortality should always be re-
ported as cumulative mortality including the reported 30-day
mortality.Complications
It is proposed to distinguish between ‘graft-’ and ‘non-graft-
related’ perioperative complications. Table 4 gives details con-
cerning non-graft-related complications.Recommendations
 All perioperative complications (‘graft-’ and ‘not graft-related’)
and the respective treatment (conservative, medical and
surgical) should be addressed.
 Any complication-related death should be documented.
E. Overall Evaluation
Microbiological and radiological ﬁndings during surveillance are
needed to assess resistance and efﬁcacy of a graft against vascular
infection. Thus, involvement of microbiologists and radiologists in
each report to ensure correct analysis of the microbiological spec-
imens and radiological imaging remains essential.
Guidelines concerning aortic VGI are based only on low levels of
evidence, level III (case-control studies and retrospective
O.E. Teebken et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 174e181 181comparative studies), level IV (case series) and level V (expert
opinion). However, following these guidelines some useful
comparisons of different study cohorts regarding abdominal VGIs
could be done. The extensive description of the study cohort and of
the study design as well as the analytical documentation of the
postoperative outcomes, as deﬁned above (Table 5), will simplify
the accomplishment of multicentre studies and meta-analyses and
will facilitate the ongoing debate regarding the best treatment
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